There were 1,110 press releases posted in the last 24 hours and 454,942 in the last 365 days.

Receive case studies from MSD, Sanofi, GSK and more at European Pharmaceutical Pricing & Reimbursement

SMi's European Pharmaceutical Pricing & Reimbursement conference will feature an array of case studies from pharma companies including MSD, Sanofi, GSK and more

LONDON, ENGLAND, UNITED KINGDOM, July 20, 2015 / -- SMi’s 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharmaceutical companies with an invaluable insight into the decision making processes and approaches of vital stakeholders. The programme will help further your understanding and enable you to develop best practice approaches to complex market access challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications though case studies presented by GSK, Sanofi, MSD and more who will be presenting at the two-day conference.

The Impact of Biosimilars and Orphan Drugs
The Impact of Biosimilars of the Market
• Analysing the characteristics of biosimilars and the development of the EU’s biosimilars market
• Exploring the likely impact of biosimilars on future pharmaceutical budgets based on different scenarios and models
• Identifying opportunities and challenges for industry, patients and payers, as well as appropriate pricing and reimbursement options – sustainable competition as a realistic option?
Alexander Roediger, Director of European Union Affairs, MSD

Purchasing Mechanisms and Working with Payers
Tiered Pricing
• Increasing market access through the development of Tiered pricing
• Understanding new mechanisms to accessing a challenging market
• Developing socioeconomic methodologies to increase medication access
Ken Walsh, Head of Emerging Markets Pricing, GSK

Case Studies in Reforms
Market Access in Turkey: Risks and opportunities in the post Healthcare Transformation Era
• Overview of Turkish Market Access & Healthcare Environment
• Basics of the Turkish Pricing & Reimbursement System
• Changing dynamics of the reimbursement system: Alternative models
• Government’s mid-long term vision on pharmaceutical industry
Toros Sahin, Head of Market Access & Health Economics, Sanofi

To view the full speaker line-up and conference programme, visit

Plus, don't miss the half-day interactive post-conference workshop:
HTA Uncovered
Led by Anke Van Engen, Principal - Advisory Services & Janice Haigh, Practice Leader Market Access, Quintiles
8.30 – 12.30 | 7th October 2015, Holiday Inn Regents Park, London, UK

Vinh Trinh
SMi Group
+44 (0) 20 7827 6140
email us here